What Could Bristol Myers Squibb (BMY) AI Antibody Deal Mean For Drug Discovery?

Bristol Myers Squibb (NYSE:BMY) announced a new collaboration with Chai Discovery to advance AI driven therapeutic antibody discovery. The agreement focuses on using artificial intelligence and machine learning to support the identification of novel therapeutic antibody candidates. The move reflects Bristol Myers Squibb's effort to integrate advanced computational tools into its drug discovery work. This type of AI focused drug discovery effort is gaining traction across biopharma, so it...